Table. 3.

Methods used for viral antigens or antibodies tests in the laboratories which participated in the second proficiency trial testing in 2018 and 2019

Test items CLIA ECLIA EIA FEIA MEIA ICA Total







2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019
Anti-HAV IgG 136 (86.1) 136 (86.1) 15 (9.5) 15 (9.5) - - 1 (0.6) 1 (0.6) - - 4 (2.5) 5 (3.2) 158 (100.0) 158 (100.0)
Anti-HAV IgM 145 (61.2) 145 (60.7) 72 (30.4) 75 (31.4) - - 17 (7.2) 16 (6.7) - - 3 (1.3) 3 (1.3) 237 (100.0) 239 (100.0)
Anti-HAV total 56 (33.7) 51 (31.1) 95 (57.2) 99 (60.4) - - 14 (8.4) 14 (8.5) - - 1 (0.6) 0 166 (100.0) 164 (100.0)
Anti-HBc IgM 49 (58.3) 49 (59.0) 27 (32.1) 27 (32.5) - - 8 (9.5) 7 (8.4) - - - - 84 (100.0) 83 (100.0)
Anti-HBc total 79 (65.3) 77 (64.7) 40 (33.1) 39 (32.8) - - 2 (1.7) 2 (1.7) - - - - 121 (100.0) 119 (100.0)
Anti-Hbe 137 (57.6) 132 (55.5) 92 (38.7) 100 (42.0) - - 9 (3.8) 6 (2.5) - - - - 238 (100.0) 238 (100.0)
HBeAg 138 (52.9) 133 (51.8) 97 (37.2) 104 (40.5) - - 9 (3.4) 6 (2.3) - - 17 (6.5) 14 (5.4) 261 (100.0) 257 (100.0)
Anti-HBs 383 (37.8) 377 (36.6) 302 (29.8) 325 (31.6) 1 (0.1) 1 (0.1) 15 (1.5) 9 (0.9) 1 (0.1) 2 (0.2) 288 (28.4) 292 (28.4) 1,014 (100.0) 1,029 (100.0)
HBsAg 390 (37.3) 386 (36.6) 314 (30.0) 331 (31.4) 1 (0.1) 1 (0.1) 24 (2.3) 12 (1.1) 1 (0.1) 2 (0.2) 292 (27.9) 297 (28.2) 1,046 (100.0) 1,055 (100.0)
Anti-HCV 350 (43.4) 340 (41.2) 208 (25.8) 229 (27.8) 3 (0.4) 3 (0.4) 10 (1.2) 7 (0.8) - - 227 (28.1) 231 (28.0) 807 (100.0) 825 (100.0)

Values are presented as number of laboratories (%).

Abbreviations: CLIA, chemiluminescence immunoassay; ECLIA, electrochemiluminescence immunoassay; EIA, enzyme immunoassay; FEIA, fluorescence EIA; MEIA, microparticle EIA; ICA, immunochromatography assay; anti-HAV, antibody to hepatitis A virus; IgG, immunoglobulin G; IgM, immunoglobulin M; anti-HBc, antibody to hepatitis B core antigen; anti-HBe, antibody to HBeAg; HBeAg, hepatitis B envelope antigen; anti-HBs, antibody to HBsAg; HBsAg, hepatitis B surface antigen; anti-HCV, antibody to hepatitis C virus.

J Lab Med Qual Assur 2020;42:166~176 https://doi.org/10.15263/jlmqa.2020.42.4.166
© Lab Med Qual Assur